|油酰乙醇胺|CsnPharm

CAS No.: 111-58-0

油酰单乙醇胺 Catalog No. CSN20649

Synonyms: N-Oleoylethanolamide;Oleamide MEA;Oleic acid monoethanolamide

Oleoylethanolamide is a lipid mediator and analog of anandamide that is involved in peripheral regulation of feeding. It is also a selective GPR55 agonist (EC50 values are 0.44, > 30 and > 30 μM at GPR55, CB1 and CB2 respectively) and PPARα agonist (EC50 = 120 nM).

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Oleoylethanolamide (OEA) is an endogenous fatty acid ethanolamide known for its anti-inflammatory effects and its influence on gut microbiota composition. Administration of OEA (20 mg/kg) produced significant improvement in a colitis model, possibly by inhibiting the nuclear factor kappa B signaling pathway through PPAR-α receptors^[3]. Treatment with OEA (5 mg/kg/day, intraperitoneal injection, i.p.) significantly attenuated the progress of liver fibrosis in both two experimental animal models by blocking the activation of hepatic stellate cells (HSCs). In vitro studies showed that OEA inhibited transforming growth factor β1-stimulated HSCs activation through suppressing Smad2/3 phosphorylation, α-SMA expression and myofibroblast transformation^[4]. OEA had also an improving effect on parameters linked to endoplasmic reticulum stress, thus demonstrating a role in the homeostatic control of protein folding^[5]. OEA has inhibitory effects on osteoclast function and survival of mature osteoclasts via GPR119-dependent and GPR119(G protein-coupled receptor 119)-independent pathways, respectively^[6].
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03347890	Obesity	Phase 4	Recruiting	March 1, 2020	Switzerland ... more >> University Hospitals of Geneva Recruiting Geneva, Switzerland, 1206 Contact: Zoltan Pataky, MD zoltan.pataky@hcuge.ch Principal Investigator: Zoltan Pataky, MD Sub-Investigator: Loic Locatelli, MD Collapse <<
NCT01851304	Obesity Overw... more >>eight Collapse <<	Not Applicable	Completed	-	Italy ... more >> Department of Agriculture and Food Science Portici, Italy, 80055 Collapse <<
NCT02243657	Healthy Subjects ... more >> Pharmacokinetics of ASP3652 Pharmacodynamics of ASP3652 Collapse <<	Phase 1	Completed	-	Netherlands ... more >> PRA International Groningen, Netherlands, 9713GZ Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 3.0719 mL
- 15.3596 mL
- 30.7192 mL
- 5 mM
- 0.6144 mL
- 3.0719 mL
- 6.1438 mL
- 10 mM
- 0.3072 mL
- 1.5360 mL
- 3.0719 mL

技术信息

CAS号

111-58-0

储存条件

粉末: Sealed in dry,Store in freezer, under -20°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C20H39NO2

运输

蓝冰

分子量

325.53

别名

N-Oleoylethanolamide;Oleamide MEA;Oleic acid monoethanolamide;Oleylethanolamide;N-Oleoylethanolamine;Activity: acid ceramidase inhibitor;NOE;AM-3101;Oleoyl Ethanolamide;N-(2-Hydroxyethyl)oleamide;N-Oleoyl-2-aminoethanol;Oleic acid ethanolamide;油酰乙醇酰胺

溶解度

DMSO	35.0 mg/mL (107.5 mM) warming
Water	insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03347890	Obesity	Phase 4	Recruiting	March 1, 2020	Switzerland ... more >> University Hospitals of Geneva Recruiting Geneva, Switzerland, 1206 Contact: Zoltan Pataky, MD zoltan.pataky@hcuge.ch Principal Investigator: Zoltan Pataky, MD Sub-Investigator: Loic Locatelli, MD Collapse <<
NCT01851304	Obesity Overw... more >>eight Collapse <<	Not Applicable	Completed	-	Italy ... more >> Department of Agriculture and Food Science Portici, Italy, 80055 Collapse <<
NCT02243657	Healthy Subjects ... more >> Pharmacokinetics of ASP3652 Pharmacodynamics of ASP3652 Collapse <<	Phase 1	Completed	-	Netherlands ... more >> PRA International Groningen, Netherlands, 9713GZ Collapse <<
NCT01223157	Obesity	Not Applicable	Completed	-	France ... more >> Service of Endocrinology, Diabetology, metabolic diseases - Hôpital du Haut Lévêque - CHU de BORDEAUX Bordeaux, France Collapse <<
NCT01092845	Healthy Sleep	Phase 1	Completed	-	United States, New York ... more >> Pfizer Investigational Site New York, New York, United States, 10019 Collapse <<
NCT01958047	Pharmacokinetics ... more >> Pharmacodynamics Healthy Subjects Effect of Race Collapse <<	Phase 1	Completed	-	United Kingdom ... more >> Parexel Early Phase Clinical Unit Harrow, United Kingdom, H1 3UJ Collapse <<
NCT02889224	Cushing's Syndrome	Not Applicable	Completed	-	France ... more >> Service d'Endocrinologie, Hopital Haut-Leveque Pessac, France, 33600 Collapse <<
NCT01964651	Healthy	Phase 1	Completed	-	Belgium ... more >> Merksem, Belgium Collapse <<
NCT03564379	Healthy	Phase 1	Completed	-	United States, California ... more >> WCCT Global, LLC Cypress, California, United States, 90630 Collapse <<
NCT03407937	Hypnosis Endo... more >>cannabinoids Analgesia Collapse <<	Not Applicable	Completed	-	Canada, Quebec ... more >> CRCHUS: Centre de recherche du centre hospitalier universitaire de Sherbrooke Sherbrooke, Quebec, Canada, J1H5N4 Collapse <<

油酰单乙醇胺 Catalog No. CSN20649

靶点选择性

请登录您的专属账户

确认信息